证券代码：603858 证券简称：步长制药 公告编号：2025-071 山东步长制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、对外担保情况概述 （一）基本情况 根据山东步长制药股份有限公司（以下简称"公司"）及下属控股子公司（含 全资子公司及非全资子公司）2025 年度的生产经营等资金需求事项，公司及控 股子公司拟向商业银行及政策性银行、金融租赁公司、金融资产管理公司、信托 公司、证券公司、保理公司、保险公司等金融机构（以下简称"金融机构"）申 请授信总额不超过人民币 69.2 亿元的综合融资额度，上述融资额度不等于公司 及控股子公司的实际融资金额，实际融资金额在总融资额度内，以金融机构与公 1 对 2025 年度公司及控股子公司不超过人民币 69.2 亿元的综合融资额度提供 担保。上述担保额度可遵照上海证券交易所相关监管规定以及公司及控股子 公司实际情况调剂使用。 该事项尚需提交公司 2024 年年度股东会审议。 被担保人名称：公司及控股子公司。 是否有反担保：将根据未来担保协议签署情 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外捐赠事项概述 证券代码：603858 证券简称：步长制药 公告编号：2025-072 山东步长制药股份有限公司 关于 2025 年度预计对外捐赠额度的公告 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第五届董事会第二十次（年度）会议，审议通过了《关于审议公司及控股子公司 2025 年度预计对外捐赠额度的议案》，同意公司及控股子公司 2025 年度预计对 外捐赠总额不超过人民币 20,000 万元（累计发生额）。公司及控股子公司 2025 年度可以在不超过上述额度范围内在帮助社会抵抗自然灾害、构建和谐生态环境、 救助危困群体、增加社会福利等公益性社会活动中捐赠财产。 本次对外捐赠额度预计事项不涉及关联交易。 本次对外捐赠资金来源于公司的自有资金，不会对公司当期及未来经营业绩 产生重大影响，亦不会损害公司及其他股东特别是中小股东利益。本次对外捐赠 事项符合公司践行向善的社会责任观，也是公司积极承担社会责任、回馈社会的 体现，有利于进一步 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-065 山东步长制药股份有限公司 第五届监事会第五次（年度）会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届监事会第五次（年 度）会议的通知于 2025 年 4 月 15 日发出，会议于 2025 年 4 月 25 日 9 时以通讯 方式召开，应到监事 4 人，实到监事 4 人，会议由监事会主席王明耿先生主持。 会议的出席人数、召开和表决方式符合《中华人民共和国公司法》等法律法规及 《山东步长制药股份有限公司章程》（以下简称"《公司章程》"）的相关规定，合 法有效。 与会监事经认真审议，通过如下议案： 1.《关于公司 2024 年度财务决算的议案》 根据《中华人民共和国公司法》及《公司章程》的相关规定，公司编制了《山 东步长制药股份有限公司 2024 年度财务决算报告》。 该议案尚需提交股东会审议。 表决结果：同意 4 票，反对 0 票，弃权 0 票。 2.《关于公司 2025 年度财务预算的议案》 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-064 山东步长制药股份有限公司 第五届董事会第二十次（年度）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届董事会第二十次（年 度）会议的通知于 2025 年 4 月 15 日发出，会议于 2025 年 4 月 25 日下午 13 时 以通讯方式召开，应参会董事 9 人，实参会董事 9 人，会议由董事长赵涛先生主 持。会议出席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法 规及《山东步长制药股份有限公司章程》的相关规定，合法有效。 经与会董事研究，会议审议通过了如下议案： 1、《关于公司 2024 年度董事会工作报告的议案》 根据《中华人民共和国公司法》及《山东步长制药股份有限公司章程》的相 关规定，为总结公司董事会 2024 年度的工作情况，董事会编制了《山东步长制 药股份有限公司 2024 年度董事会工作报告》。 该议案尚需提交股东会审议。 表决结果：同意 9 票，反对 0 票，弃权 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-066 山东步长制药股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配方案内容 （一）利润分配方案及情况说明 经信永中和会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 山东步长制药股份有限公司（以下简称"公司"）母公司期末未分配利润为人民 币 5,365,632,450.38 元，2024 年度公司实现归属于上市公司股东的净利润为人 民币-553,797,938.80 元。经董事会决议，本次利润分配方案如下： 公司 2024 年度拟不派发现金红利，不进行资本公积金转增股本，不送红股。 公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简称 "《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 本次利润分配方案尚须提交公司股东会审议批准。 （二）是否可能触及其他风险警示情形 单位：元 | 项目 | | ...

| 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 步长(香港)控股有限公司 | 49095.72 | 44.39 | 不变 | | 首诚国际(香港)有限公司 | 8274.24 | 7.48 | 不变 | | 山东步长制药（603858）股份有限公司回购专用 | 4485.36 | 4.06 | 不变 | | 刘少鸾 | 2645.90 | 2.39 | 不变 | | 杨伟 | 2203.01 | 1.99 | 不变 | | 西藏丹红企业管理有限公司 | 2040.84 | 1.85 | 不变 | | 蓝色经济区产业投资基金(有限合伙) | 1034.28 | 0.94 | 不变 | | 黄定旺 | 977.97 | 0.88 | 4.44 | | 香港中央结算有限公司 | 843.56 | 0.76 | -25.28 | | 南方中证500ETF | 773.51 | 0.70 | -25.00 | | 较上个报告期退出前十大股东有 | | | | | 苏州联胜化学有限公司 | 690.60 | 0.62 | 退出 | ...

山东步长制药股份有限公司 关于变更回购股份用途并注销暨减少注册资本的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603858 证券简称：步长制药 公告编号：2025-075 山东步长制药股份有限公司（以下简称"公司"）于2025年4月25日召开第五届董 事会第二十次（年度）会议及第五届监事会第五次（年度）会议，审议通过了《关于 变更回购股份用途并注销暨减少注册资本的议案》，公司拟将存放于公司回购专用证 券账户的44,853,573股股份用途变更为"减少公司注册资本"，并按照《中华人民共 和国公司法》《中华人民共和国证券法》及《上海证券交易所上市公司自律监管指引 第7号——回购股份》等相关规定进行注销，并按相关规定办理注销手续。 本次变更回购股份用途并注销暨减少注册资本事项尚需提交公司股东会审议。现 将有关事项公告如下： 一、回购股份方案及实施情况 公司于 2023 年 12 月 13 日召开第四届董事会第四十七次会议，审议通过了《关于 1 变更回购股份用途：公司拟将2023年回购方案的回购股 ...

山东步长制药股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/12/27 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 √用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 6,620,630股 | | 累计已回购股数占总股本比例 | 0.60% | | 累计已回购金额 | 9,803.75万元 | | 实际回购价格区间 | 13.86元/股~15.07元/股 | 证券代码：603858 证券简称：步长制药 公告编号：2025-080 一、回购股份的基本情况 山东步长制药股份有限公司（以下简称"公司"）于 2024 年 12 月 26 日召开 第五届董事会第十一次会议，审议通过了《关于以集中竞价交易方式回购股份的 方 ...

Financial Performance - In 2024, the company reported a net profit attributable to shareholders of negative value, leading to a decision not to distribute cash dividends or increase capital reserves[6]. - The company's operating revenue for 2024 was CNY 11,005,794,900.15, a decrease of 16.91% compared to CNY 13,245,133,303.78 in 2023[23]. - The net profit attributable to shareholders was -CNY 553,797,938.80 in 2024, representing a decline of 273.62% from CNY 318,973,324.80 in 2023[23]. - The basic earnings per share for 2024 was -CNY 0.5110, down 277.18% from CNY 0.2884 in 2023[24]. - The company reported a net cash flow from operating activities of CNY 939,950,568.92 in 2024, a significant recovery from -CNY 195,605,226.23 in 2023[23]. - The total assets at the end of 2024 were CNY 19,328,509,108.36, a decrease of 7.48% from CNY 20,892,297,542.28 at the end of 2023[23]. - The company’s weighted average return on equity was -5.07% in 2024, a decrease of 7.73 percentage points from 2.66% in 2023[24]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[154]. - The company reported a total revenue of 1.4 billion RMB for the fiscal year 2024, reflecting a year-on-year growth of 15%[159]. - The company reported a net loss attributable to ordinary shareholders of approximately 553.8 million RMB for the most recent fiscal year[189]. Shareholder Actions - The total amount spent on share repurchases was CNY 710,527,866.30, with plans to cancel the repurchased shares after shareholder approval[6]. - The cumulative cash dividend amount over the last three fiscal years was approximately 1.1974 billion RMB[191]. - The total amount for share repurchases and cancellations over the last three fiscal years was approximately 933.99 million RMB[191]. - The total cash dividend and share repurchase amount over the last three fiscal years reached approximately 2.1314 billion RMB[191]. - The company's retained earnings at the end of the most recent fiscal year were approximately 5.3656 billion RMB[191]. Risk Management - The company has outlined various risks in its operations, including industry and management risks, which are detailed in the management discussion section[8]. - The company has a comprehensive risk management strategy in place to address potential operational challenges[8]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not faced any situations where more than half of the directors could not guarantee the authenticity of the annual report[8]. - The company faces risks related to drug price reductions due to national policy influences, which may compress profit margins[140]. Research and Development - The company applied for 35 new patents in 2024 and successfully obtained 27 patents, including 9 invention patents[34]. - The company is developing 12 biological products targeting major diseases such as tumors and osteoporosis, with some products entering the NDA application stage[35]. - The company has a diverse pipeline of products under development, focusing on major disease areas such as cardiovascular, gynecology, diabetes, malignant tumors, digestive, and respiratory systems[62]. - The company is actively engaged in vaccine research and development, with multiple products in various stages, including flu and meningococcal vaccines[60]. - The company is enhancing its understanding and investment in biopharmaceuticals, with plans to complete the production base in Luzhou, Sichuan[131]. - The company has established a research and development model that combines independent innovation with external technical cooperation, enhancing its technological capabilities[101]. - The company is focusing on research and development of new products and technologies to drive future growth[150]. Market Strategy - The company aims to leverage clinical data to validate product efficacy and enhance market reputation, thereby driving sales growth[33]. - The company aims to establish a comprehensive health industry chain, including investments in medical devices, cosmetics, disinfectants, health products, and health foods[35]. - The company is actively expanding into various therapeutic areas, including gynecology, urology, diabetes, and malignant tumors, while leveraging its traditional strengths in traditional Chinese medicine[53]. - The company is focused on integrating traditional Chinese medicine with modern pharmaceutical processes to enhance treatment efficacy[35]. - The company plans to enhance its marketing budget by 25% to support new product launches and brand awareness initiatives[156]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB earmarked for this purpose[154]. Governance and Compliance - The board of directors and supervisory board members have confirmed the authenticity and completeness of the annual report[3]. - The company has established a governance structure compliant with relevant laws and regulations, ensuring independent operation of its board and management[147]. - The company is committed to strict compliance with legal regulations and internal guidelines in all committee activities[173][174][175]. - The company is revising its internal governance documents, including the Articles of Association and decision-making rules for related transactions[165]. - The company has proposed to revise its articles of association and governance rules to enhance operational efficiency and compliance[150]. Employee and Talent Management - The total number of employees in the parent company is 1,735, while the total number of employees in major subsidiaries is 5,954, resulting in a combined total of 7,689 employees[180]. - The company has established effective talent introduction and training mechanisms to enhance its innovation capabilities[36]. - The training plan includes establishing a talent growth platform, multi-level training based on employee roles, and integrating training assessments into performance evaluations[183]. - The company emphasizes a fair salary policy based on external and internal equity, market principles, strategic orientation, and economic principles[182]. Environmental Responsibility - The company invested approximately 8.6791 million RMB in environmental protection during the reporting period[198]. - The total annual discharge of chemical oxygen demand from the factory was 41.6 tons, with a concentration of 91.1 mg/L[199]. - The total annual discharge of ammonia nitrogen was 0.1892 tons, with a concentration of 0.408 mg/L[199].

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,784,946,981.48, representing a 5.47% increase compared to ¥2,640,556,945.44 in the same period last year[3]. - Net profit attributable to shareholders increased by 169.49% to ¥307,261,088.17 from ¥114,015,551.69 year-on-year[3]. - Net profit for Q1 2025 was ¥289,890,204.09, significantly up from ¥87,698,871.86 in Q1 2024, representing a growth of 230.5%[16]. - Basic and diluted earnings per share rose by 180.10% to ¥0.2899 from ¥0.1035 in the same period last year[3]. - Earnings per share for Q1 2025 was ¥0.2899, compared to ¥0.1035 in Q1 2024, reflecting a substantial increase[16]. Cash Flow - The net cash flow from operating activities surged by 814.82% to ¥678,016,314.81, up from ¥74,114,961.92 in the previous year[3]. - Cash flow from operating activities for Q1 2025 was ¥678,016,314.81, a significant increase from ¥74,114,961.92 in Q1 2024, representing a growth of approximately 815.5%[20]. - Total cash inflow from operating activities in Q1 2025 reached ¥2,992,606,467.80, compared to ¥2,749,269,900.40 in Q1 2024, indicating an increase of about 8.8%[20]. - The total cash inflow from operating activities was primarily driven by an increase in cash received from sales, which amounted to ¥2,929,463,148.12 in Q1 2025, compared to ¥2,649,327,706.77 in Q1 2024[20]. - The company reported a decrease in cash paid for goods and services, which was ¥526,854,643.76 in Q1 2025, down from ¥636,791,962.37 in Q1 2024, indicating a reduction of approximately 17.3%[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥19,836,965,205.27, a 2.63% increase from ¥19,328,509,108.36 at the end of the previous year[3]. - Total current assets increased to ¥8,090,878,234.09 as of March 31, 2025, up from ¥7,537,198,596.50 at the end of 2024[11]. - Total liabilities rose to ¥9,786,024,120.20 as of March 31, 2025, compared to ¥9,520,425,198.24 at the end of 2024[12]. - The company reported a total asset value of ¥19,836,965,205.27 as of March 31, 2025, an increase from ¥19,328,509,108.36 at the end of 2024[12]. - The company’s total equity increased to ¥10,050,941,085.07 as of March 31, 2025, up from ¥9,808,083,910.12 at the end of 2024[12]. Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.53% to ¥10,475,032,314.12 from ¥10,216,464,921.09[3]. - The weighted average return on equity increased by 1.99 percentage points to 2.97%[3]. Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥7,672,820.13 for the period[5]. Strategic Developments - The increase in net profit was primarily driven by higher sales volume and changes in product sales structure, along with the acquisition of Tonghua Guhong Pharmaceutical Co., Ltd.[6]. - The company has not disclosed any new product or technology developments, market expansion, or merger and acquisition strategies in this report[10]. Cash Flow from Investing and Financing Activities - Cash outflow from investing activities in Q1 2025 was ¥339,677,008.39, a substantial rise from ¥87,326,830.66 in Q1 2024, reflecting an increase of approximately 288.5%[20]. - Net cash flow from investing activities for Q1 2025 was -¥336,787,235.62, worsening from -¥86,404,964.15 in Q1 2024[20]. - Cash inflow from financing activities in Q1 2025 totaled ¥683,395,102.72, down from ¥950,358,691.77 in Q1 2024, a decrease of about 28.1%[20]. - Net cash flow from financing activities for Q1 2025 was ¥272,065,937.17, compared to ¥332,495,910.56 in Q1 2024, showing a decline of approximately 18.2%[20]. Accounting Standards - The company did not apply new accounting standards for the first time in 2025, as stated in the announcement[21].